Chemoembolization versus radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma in a single institution image-based efficacy and comparative toxicity

Akinwande, Olaguoke; Shah, Veer; Mills, A. K.; Noda, Christopher; Weiner, Eric J.; Foltz, Gretchen; Saad, Nael

doi:10.2217/hep-2017-0005

Cited by 14 publications

(19 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After implementing our exclusion criteria, 47 papers were eligible for data extraction. Of the final 47 included papers, 40 were journal articles [ 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 ] ( Table 1 ), and seven were conference abstracts [ 62 , 63 , 64 , 65 , 66 , 67 , 68 ] ( Table 2 ).…”

Section: Resultsmentioning

confidence: 99%

Selective Internal Radiation Therapy with Yttrium-90 for Intrahepatic Cholangiocarcinoma: A Systematic Review on Post-Treatment Dosimetry and Concomitant Chemotherapy

et al. 2022

View full text Add to dashboard Cite

Selective internal radiation therapy (SIRT) with yttrium-90 (90Y)-loaded microspheres is increasingly used for the treatment of Intrahepatic Cholangiocarcinoma (ICC). Dosimetry verifications post-treatment are required for a valid assessment of any dose-response relationship. We performed a systematic review of the literature to determine how often clinics conducted post-treatment dosimetry verification to measure the actual radiation doses delivered to the tumor and to the normal liver in patients who underwent SIRT for ICC, and also to explore the corresponding dose-response relationship. We also investigated other factors that potentially affect treatment outcomes, including the type of microspheres used and concomitant chemotherapy. Out of the final 47 studies that entered our study, only four papers included post-treatment dosimetry studies after SIRT to quantitatively assess the radiation doses delivered. No study showed that one microsphere type provided a benefit over another, one study demonstrated better imaging-based response rates associated with the use of glass-based TheraSpheres, and two studies found similar toxicity profiles for different types of microspheres. Gemcitabine and cisplatin were the most common chemotherapeutic drugs for concomitant administration with SIRT. Future studies of SIRT for ICC should include dosimetry to optimize treatment planning and post-treatment radiation dosage measurements in order to reliably predict patient responses and liver toxicity.

show abstract

Section: Resultsmentioning

confidence: 99%

Selective Internal Radiation Therapy with Yttrium-90 for Intrahepatic Cholangiocarcinoma: A Systematic Review on Post-Treatment Dosimetry and Concomitant Chemotherapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…One retrospective single-center study evaluated efficacy and toxicity of TACE (24 conventional TACE and 7 drug-eluting beads TACE) and Y 90 -TARE in the treatment of iCCA. 32 There were a total of 40 patients, of whom 25 received Y 90 -TARE and 15 received TACE. Patients in both groups had similar baseline characteristics.…”

Section: Comparison Of Tace Versus Y 90 -Tare For Iccamentioning

confidence: 99%

Radioembolization for Cholangiocarcinoma

Ali

Manzoor

Weinstein

et al. 2021

Digestive Disease Interventions

View full text Add to dashboard Cite

Cholangiocarcinoma is the second most common primary hepatic malignancy which accounts for 13% of total cancer mortality worldwide. Surgical resection is the only curative treatment for localized disease; however, the majority of patients present when the tumor is unresectable. The incidence of the intrahepatic subtype of cholangiocarcinoma is increasing worldwide. Current standard of care in patients with unresectable intrahepatic cholangiocarcinoma is systemic chemotherapy; however, yttrium-90 transarterial radioembolization (Y90-TARE) is under investigation for the treatment of intrahepatic cholangiocarcinoma with promising trials and published clinical experience. This review critically evaluates the role of Y90-TARE in the management of intrahepatic cholangiocarcinoma.

show abstract

“…İKK, safra kesesi kanseri olan 410 kişiden oluşan bir faz 3 çalışmasında, gemsitabin ve gemsitabin+sisplatin kombinasyonlu kemoterapi tedavilerinin etkinliği araştırılmıştır. Gemsitabin verilen grupta medyan sağkalım oranı 8,1 ay ve gemsitabin+sisplatin verilen grupta 11,7 ay olarak bulunmuştur 7 . Bu iki tedavi türü kıyaslandığında anlamlı bir farklılık olsa da sağkalım süresini 12 ayın üzerine çıkaramamıştır.…”

Section: İstatistiksel Analizunclassified

“…Cerrahi tedavi uygulanamayan İKK hastalarında başlangıç tedavi olarak sistemik kemoterapi veya intraarteriyel tedaviler, perkütan ablasyon, eksternal radyoterapi gibi tedaviler uygulanmaktadır 6 . Rezeke edilmeyen İKK hastalarında günümüzde ilk seçenek sistemik kemoterapidir ve gemsitabin tabanlı tedavi protokolleri uygulanmaktadır 7 . Ancak sistemik kemoterapinin toksik etkileri yüksektir 8 .…”

Section: Introductionunclassified

See 1 more Smart Citation

İntrahepatik kolanjiyosellüler karsinomlarda transarteriyel radyoembolizasyon tedavisinin sağkalım üzerine etkisi

Balli

Güney

Pişkin

et al. 2019

Cukurova Medical Journal

View full text Add to dashboard Cite

The aim of this study was to present the survival analyses of patients with intrahepatic cholangiocellular carcinoma who are ineligible forsurgical treatment and treated with transarterial radioembolization. Materials and Methods: Twenty-eight patients with intrahepatic cholangiocellular carcinoma who were not eligible for surgical treatment were included in this study. All patients were treated by transarterial radioembolization. The survival time of the patients who were followed up after diagnosis was recorded. Kaplan-Meier survival analysis was used to calculate survival. Results: The mean age was 60.46 years. While minimum age of patients was 36 years, maximum age of patients 84 years. The median follow-up was 14 months (min:3, max:33). The median survival time of the patients was 22 months (min:3 months, max:33 months). In addition, the survival time of patients who received chemotherapy and patients who did not receive chemotherapy, patients with solitary tumor, patients with multifocal tumor, patients with tumor unilobar and patients with bilobar were calculated and no significant difference was found between the groups. Conclusion: Although modern chemotherapy has increased this survival rate, it has not been able to increase the median survival beyond 12 months. When these data are taken into consideration, it is seen that transarterial radioembolization treatment prolongs survival. Amaç: Bu çalışmanın amacı, cerrahi tedaviye uygun olmayan ve transarteriyel radyoembolizasyon yöntemi ile tedavi edilen intrahepatik kolanjiyosellüler karsinom hastalarının sağkalım sonuçlarını sunmaktır. Gereç ve Yöntem: Bu çalışmaya intrahepatik kolanjiyosellüler karsinom tanısı almış ve cerrahi tedaviye uygun olmayan 28 hasta dahil edildi. Hastaların tamamı transarteriyel radyoembolizasyon yöntemi ile tedavi edildi. Tanı konduktan sonra takipleri başlayan hastaların sağkalım süreleri kayıt altına alındı. Sağkalım süreleri hesaplanırken Kaplan-Meier yaşam analizi kullanıldı. Bulgular: Çalışmada toplamda 28 hasta değerlendirilmiştir. Ortalama yaş 60,46 yıl olup minimum yaş 36 yıl, maksimum yaş ise 84 yıldır. Hastaların medyan takip süresi 14 ay olarak hesaplandı (min:3-maks:33). Hastaların medyan sağkalım süresi 22 (min:3 ay, max:33 ay) aydır. Ayrıca kemoterapi almış hastalar ile almamış hastalar, soliter tümörü olan hastalar ile multifokal tümörü olan hastalar, tümörü unilobar olan hastalar ile bilobar olan hastaların sağkalım süreleri hesaplandı ve gruplar arasında anlamlı bir farklılık bulunmadı. Sonuç: Modern kemoterapi uygulamaları bu sağkalım oranında artış sağlamış olsa da medyan sağkalımı 12 ayın üzerine çıkaramamıştır. Bu veriler dikkate alındığında transarteriyel radyoembolizasyon tedavisinin sağkalım süresini uzattığı görülmektedir.

show abstract

Chemoembolization versus radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma in a single institution image-based efficacy and comparative toxicity

Abstract: Our observation shows that CE and Y90 display similar toxicity and disease control in the treatment of UICC.

Cited by 14 publications

References 42 publications

Selective Internal Radiation Therapy with Yttrium-90 for Intrahepatic Cholangiocarcinoma: A Systematic Review on Post-Treatment Dosimetry and Concomitant Chemotherapy

Selective Internal Radiation Therapy with Yttrium-90 for Intrahepatic Cholangiocarcinoma: A Systematic Review on Post-Treatment Dosimetry and Concomitant Chemotherapy

Radioembolization for Cholangiocarcinoma

İntrahepatik kolanjiyosellüler karsinomlarda transarteriyel radyoembolizasyon tedavisinin sağkalım üzerine etkisi

Contact Info

Product

Resources

About